Clinical Trials on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

Total 4 results

Xiang Xie
Xinjiang Medical University

Not yet recruiting

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Cancer | Atherosclerotic Cardiovascular Disease | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Tianjin Chest Hospital

Recruiting

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome (EMSIACS)

Acute Coronary Syndrome | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Rhythm Pharmaceuticals, Inc.

Completed

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations

United States, Israel, Canada, Germany, Greece, Italy, Portugal

3

Subscribe